This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Topic Collections  • Aging/ Geriatrics  • Oncology  • Oncology, Other  • Prognosis/ Outcomes  • Drug Therapy  • Adverse Effects  • Drug Therapy, Other  • Hematology/ Hematologic Malignancies  • Anemias  • Alert me on articles by topic  Social Bookmarking   What's this?

Tracy Hampton, PhD

JAMA. 2008;300(2):155-156.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Chicago—New research findings in the field of personalized medicine could help oncologists understand the characteristics that determine why patients respond differently to therapeutic drugs. The studies were presented recently at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO).

New research indicates that many older patients take medications that can interfere with the efficacy of anticancer drugs. (Photo credit: Britta Kasholm-Tengve/iStockphoto.com)

"This exciting field gives cancer doctors new tools to identify the most appropriate treatment for each patient while avoiding overtreatment with drugs that have potentially toxic side effects," said Julie Gralow, MD, chair of ASCO's cancer communications committee and associate professor of medicine at the University of Washington in Seattle.

NEW RNA TEST

One study of interest assessed the effect on cancer outcomes of erythropoietin, which is commonly prescribed to treat anemia in patients with cancer. A number of phase 3 clinical trials . . . [Full Text of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?